ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University. Read our paper here: Minimal Crossover between Mutations Associated...
Feb 16, 2022
SINGAPORE, SAN DIEGO, OKLAHOMA CITY, and AUSTIN – February 16, 2022 – ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of...
Jun 29, 2021
SINGAPORE and SAN DIEGO – June 29, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune...
Apr 14, 2021
SINGAPORE and SAN DIEGO – April 14, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human...
Mar 30, 2021
ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University to better understand if the CD8+ T-cell responses from COVID-19...
Mar 9, 2021
Helsinki, Finland, 9 March 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel and adaptable immunotherapy platforms for cancer and infectious diseases,...
Feb 22, 2021
SINGAPORE and SAN DIEGO – February 23, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human...
Jan 28, 2021
SINGAPORE and SAN DIEGO – January 28, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human...
Jan 26, 2021
ImmunoScape is thrilled to announce its collaboration with Johns Hopkins University/NIAID to deeply profile the SARS-CoV-2-specific CD8 T cell response in COVID-19...